Neuronetics, Inc. CFO Stephen Furlong Sells Shares

On February 12th, CFO Stephen Furlong of Neuronetics, Inc. (NASDAQ:STIM - Get Free Report) sold 10,845 shares of the company’s stock. The transaction was completed at an average price of $3.83 per share, resulting in a total sale value of $41,536.35. Following this sale, Furlong holds a total of 471,727 shares, which has an estimated value of $1,806,714.41. This sale represents a decrease of 2.25% in his ownership stake in the company. Additionally, this transaction was disclosed through a filing with the Securities and Exchange Commission (SEC).

Furlong made another transaction just prior to the sale on February 10th, where he sold 14,836 shares at an average price of $3.28, culminating in a total value of $48,662.08.

Performance of Neuronetics Stock

As of recent trading on Friday, shares of Neuronetics opened at $4.36. Over the past year, the stock has witnessed a low of $0.52 and a high of $5.07. The company has maintained a 50-day simple moving average of $2.20 along with a 200-day simple moving average of $1.42. Key financial ratios for Neuronetics include a quick ratio of 2.87, a current ratio of 3.16, and a debt-to-equity ratio of 4.90, indicating its financial health.

Institutional Investor Movement

Various institutional investors have recently shown interest in Neuronetics stock, either increasing or reducing their stakes. GSA Capital Partners LLP raised its position by 64.5% during the third quarter, holding now 78,642 shares valued at around $60,000 after purchasing an additional 30,837 shares. Additionally, Landscape Capital Management L.L.C. acquired new shares worth about $53,000 in the same period. HighTower Advisors LLC boosted its holdings by 55.5%, now owning 245,982 shares valued at $187,000 after adding 87,816 shares. David J Yvars Group reported a 47.1% increase in its stake during the fourth quarter, resulting in 46,325 shares valued at $75,000. Lastly, JPMorgan Chase & Co. significantly increased its holdings by 10,954.1%, owning 54,939 shares valued at approximately $88,000 after purchasing 54,442 additional shares. Institutional investors collectively own about 53.59% of Neuronetics stock.

Company Overview

Neuronetics, Inc. is recognized as a commercial stage medical technology firm that specializes in designing, developing, and marketing products aimed at patients suffering from neurohealth disorders, both in the United States and internationally. Notably, the company offers the NeuroStar Advanced Therapy System, a non-invasive office-based treatment for adult patients with major depressive disorder.

Neuronetics, Shares, Transaction